Editas Medicine (EDIT) EPS (Weighted Average and Diluted) (2019 - 2025)
Editas Medicine (EDIT) reported EPS (Weighted Average and Diluted) of -$0.28 for Q3 2025, up 62.67% year-over-year from -$0.17 in Q3 2024, and up 55.56% on a QoQ basis from -$0.63 in Q2 2025.
Editas Medicine (EDIT) has 7 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.28 in Q3 2025.
- Quarterly EPS (Weighted Average and Diluted) rose 62.67% year-over-year to -$0.28 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$2.38 (up 6.3% YoY) and the FY2024 annual result came in at -$2.88, down 42.57% from the prior year.
- EPS (Weighted Average and Diluted) improved to -$0.28 in Q3 2025 per EDIT's latest filing, from -$0.63 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at -$0.21 in Q4 2023 and bottomed at -$0.92 in Q1 2025.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.74 (2022), against an average of -$0.67.
- The widest annual swing landed in 2021, when EPS (Weighted Average and Diluted) slumped 575.0%; it then jumped 76.14% in 2023.
- Tracing EDIT's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.61 in 2021, then sank by 44.26% to -$0.88 in 2022, then jumped by 76.14% to -$0.21 in 2023, then slumped by 161.9% to -$0.55 in 2024, then jumped by 49.09% to -$0.28 in 2025.
- Per Business Quant, the three latest EDIT EPS (Weighted Average and Diluted) figures stand at -$0.28 (Q3 2025), -$0.63 (Q2 2025), and -$0.92 (Q1 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.51 |
| 10 | Editas Medicine | 338.62 Mn | 338.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -0.28 |
| Jun 30, 2025 | -0.63 |
| Mar 31, 2025 | -0.92 |
| Dec 31, 2024 | -0.55 |
| Sep 30, 2024 | -0.75 |
| Jun 30, 2024 | -0.82 |
| Mar 31, 2024 | -0.76 |
| Dec 31, 2023 | -0.21 |
| Sep 30, 2023 | -0.55 |
| Jun 30, 2023 | -0.56 |
| Mar 31, 2023 | -0.71 |
| Dec 31, 2022 | -0.88 |
| Sep 30, 2022 | -0.81 |
| Jun 30, 2022 | -0.78 |
| Mar 31, 2022 | -0.74 |
| Dec 31, 2021 | -0.61 |
| Sep 30, 2021 | -0.57 |
| Jun 30, 2021 | -0.81 |
| Mar 31, 2021 | -0.86 |
| Dec 31, 2020 | -1.05 |
| Sep 30, 2020 | 0.12 |
| Dec 31, 2019 | -0.73 |
| Sep 30, 2019 | -0.66 |